Video

Nadia Waheed, MD, MPH: OCT Angiography Predicts DR Progression

Author(s):

A new study from AAO 2020 is the first to show a significant association between peripapillary vessel density loss and progression of diabetic retinopathy.

A study presented at the American Academy of Ophthalmology (AAO) 2020 Virtual Conference showed that optical coherence tomography (OCT) angiography metrics at baseline have the potential to predict risk of diabetic retinopathy progression at year 1.

The investigators performed color fundus photography as well as 3x3 and 6x6 macular scans, which were analyzed by a reading center.

They defined disease progression as either a ≥2-step increase in DRSS score or the development of diabetic macular edema (DME).

Thus, they enrolled a total of 167 individuals, 77 of which were affiliated with sites that had OCT angiography machines available. Within that subgroup, 73 patients had long-term progression data over the course of 1 year.

Enrolled patients were ≥18 years, had moderate-to severe diabetic retinopathy (ETDRS 43-53), had no center involved (DME), and had best correct visual acuity (BCVA) ≥ 70.

According to their multivariate logistic regression analysis, diabetic retinopathy progression was associated with enlarged foveal avascular zone (FAZ) area (4.75; OR, 115.6; P = .019), the presence of intraretinal microvascular abnormalities (IrMA) (3.00; OR, 20.09; P = .008), and decreased temporal peripapillary vessel density (superior and inferior).

In an interview with HCPLive®, study investigator Nadia Waheed, MD, MPH, Retina Specialist and Associate Professor, Tufts University School of Medicine, suggested that these associations were not particulary surprising.

“Intuitively, we’ve always known that,” she said. “We do fluorescein angiography to give us an idea of how the patient is doing and how the patient’s vasculature is doing. And this is kind of just a direct correlate to that.”

Related Videos
Highlighting Recent Therapies for Dermatologists, with James Del Rosso, DO
Ladan Zand, MD: Obinutuzumab Promising Option for Refractory, Primary FSGS
Rahul N. Khurana, MD: Phase 1 Results on Vamikibart for Uveitic Macular Edema | Image Credit: Northern California Retina Vitreous Associates
Sunir J. Garg, MD: | Image Credit: Wills Eye Hospital
James Del Rosso, DO: Discussing What’s New in the Medicine Chest for Dermatologists
What to Look Forward To at the Fall Clinical Dermatology Conference, with Raj Chovatiya, MD, PhD
Christine N. Kay, MD: Interim Data on ATSN-201 Shows Promise for XLRS | Image Credit: Vitreo Retinal Associates
Arshad Khanani, MD: First Results from Fellow Eye Dosing of RGX-314 in nAMD | Image Credit: Sierra Eye Associates
Jonathan Barratt, MD | Credit: IgA Nephropathy Foundation
© 2024 MJH Life Sciences

All rights reserved.